ofloxacin otic solution 0.3%

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media

Conditions

Otitis Media

Trial Timeline

Nov 1, 2002 → Apr 1, 2003

NCT ID

NCT00781521

About ofloxacin otic solution 0.3%

ofloxacin otic solution 0.3% is a phase 3 stage product being developed by Daiichi Sankyo for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00781521. Target conditions include Otitis Media.

What happened to similar drugs?

2 of 11 similar drugs in Otitis Media were approved

Approved (2) Terminated (2) Active (7)

🔄levofloxacinJohnson & JohnsonPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccineMerckPhase 3

🔄ZmaxPfizerPhase 3

✅Saline + Fentanyl + Dexmedetomidine + DexmedetomidinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00781521	Phase 3	Completed	Nov 1, 2002	Apr 1, 2003	Otitis Media

Competing Products

15 competing products in Otitis Media

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine	Merck	Phase 3	40
Prevenar	Pfizer	Pre-clinical	26
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
Telithromycin (HMR3647)	Sanofi	Phase 3	40
telithromycin (HMR3647)	Sanofi	Phase 3	32
Telithromycin + Azithromycin	Sanofi	Phase 3	32